Quantity of qualified patients: CDEC reviewed the uncertainty in the volume of people with reasonably significant to extreme hemophilia B in Canada suitable for etranacogene dezaparvovec. Clinical authorities consulted by CADTH indicated that some sufferers that are classified as obtaining gentle or average disorder could possibly have a significant bleeding https://colettej791ccc3.wikicarrier.com/user